INTERVIEW

Ex-Minister Tamura: 3 New Sources of Social Security Funding Needed to Stem Overreliance on Drug Price Cuts

By Yoshinori Sagehashi April 3, 2019
The Japanese cost-effectiveness assessment (CEA) scheme is not yet another tool to trim drug spending but a science-based policy that would make drug prices more palatable for stakeholders with conflicting interests, former health minister Norihisa Tamura says. In his interview…

To read the full story

Related Article

INTERVIEW

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Takashi Ebisawa

Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

By Yoshinori Sagehashi

Japan positions its new cost-effectiveness assessment (CEA) scheme merely as a tool to complement the current drug pricing system, but…

Tatsuya Kondo, chief executive of the Pharmaceuticals and Medical Devices Agency (PMDA), is hitting the exit at the end of…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Reiji Anasako

With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…